Better therapeutic trials in ovarian cancer

Journal of the National Cancer Institute

Volumn 106, Issue 4, 2014, Pages

  Bookman, Michael A ^a   Gilks, C Blake ^b   Kohn, Elise C ^c   Kaplan, Karen O ^d   Huntsman, David ^e,g   Aghajanian, Carol ^h   Birrer, Michael J ⁱ   Ledermann, Jonathan A ^j   Oza, Amit M ^k   Swenerton, Kenneth D ^f  

^a UNIVERSITY OF ARIZONA   (United States)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Prevent Cancer Foundation   (United States)

^e Pathology and Laboratory Medicine   (Canada)

^f Department of Medical Oncology ^*  (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k PRINCESS MARGARET HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; BLOOD; CANCER GRADING; CANCER STAGING; COLLOID CARCINOMA; CYSTADENOCARCINOMA; DRUG INDUSTRY; DRUG SCREENING; ENDOMETRIOID CARCINOMA; FEMALE; FINANCIAL MANAGEMENT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MUTATION; NATIONAL HEALTH ORGANIZATION; OVARY TUMOR; PATHOLOGY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STANDARD; UNITED STATES;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DRUG INDUSTRY; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84898857497     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju029     Document Type: Review

References (38)

1. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer-a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433.
2. Singer G, Oldt R III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95(6):484-486.
3. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28(4):496.
4. Ali RH, Seidman JD, Luk M, Kalloger S, Gilks CB. Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant Brenner tumor. Int J Gynecol Pathol. 2012;31(6):499-506
5. Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008;39(8):1239-1251.
6. Köbel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol. 2010;34(7):984-993.
7. Malpica A, Deavers MT, Tornos C, et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol. 2007;31(8):1168-1174.
8. Folkins AK, Jarboe EA, Roh MH, Crum C P. Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol. 2009;113(3):391-396.
9. Piek JM., van Diest PJ, Zweemer R P, et al. Dysplastic changes in prophy-lactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195(4):451-456.
10. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211(1):26-35.
11. McMeekin DS, Burger RA, Manetta A, DiSaia P, Berman ML. Endometrioid adenocarcinoma of the ovary and its relationship to endo-metriosis. Gynecol Oncol. 1995;59(1):81-86.
12. Modesitt SC, Tortolero-Luna G, Robinson JB, Gershenson DM, Wolf JK. Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol. 2002;100(4):788-795.
13. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532- 1543.
14. Chan A, Gilks CB, Kwon J, Tinker A. New insights into the pathogen-esis of ovarian carcinoma: time to rethink ovarian cancer screening. Obstet Gynecol. 2012;20(4):935-940.
15. Grisham RN, Iyer G, Garg K, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2013;119(3):548-554.
16. Wong KK, Tsang YT, Deavers MT, et al. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010;177(4):1611-1617.
17. Pegram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res. 2000;103:57-75.
18. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
19. Alsop K, Fereday S, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654-2663.
20. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134.
21. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245- 251.
22. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852-861.
23. Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372-379.
24. Adams S F, Marsh EB, Elmasri W, et al. A high response rate to liposo-mal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol. 2011;123(3):486-491.
25. Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14(2):134-140
26. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian cancer. Nature. 2011;474(7353):609-615.
27. Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198-5208.
28. Anglesio MS, George J, Kulbe H, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res. 2011;17(8):2538-2548.
29. Stany MP, Vathipadiekal V, Ozbun L, et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 2011;6(7):e21121.
30. Anglesio MS, Kommoss S, Tolcher MC, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013;229(1):111-120.
31. McDermott DF, Manola J, Pins M, et al. The BEST trial (E2804): a randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC). J Clin Oncol. 2013;31(Supp):345.
32. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97-100.
33. Hunsberger S, Zhao Y, Simon R. A comparison of phase II study strategies. Clin Cancer Res. 2009;15(19):5950-5955.
34. Parmar MK, Barthel FM, Sydes M, et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst. 2008;100(17):1204-1214.
35. Sydes MR, Parmar MK, Mason MD, et al. Flexible trial design in practice-stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;13:168.
36. McGuire III W P, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6.
37. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2000;18(1):106-115.
38. Bashashati A, Ha G, Tone A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial muta-tional profiling. J Pathol. 2013;231(1):21-34.